inclusion criteria: 1. hospitalized or will be hospitalized prior to randomization for the treatment of severe covid-19 with sars-cov-2 infection confirmed by either a) a positive reverse transcriptase polymerase chain reaction (rt pcr) or b) an antigen-based test from any respiratory, nasopharyngeal, saliva, blood, or stool specimen at screening or documented within 1 week prior to the start of screening (severe covid-19 is defined as confirmed disease in patients who are hospitalized with hypoxia \[spo2 ≤93% on room air\], respiratory rate \>30, pao2/fio2 \<300, but do not require imv). 2. age ≥ 18 years 3. platelet count ≥ 50,000/µl 4. if fertile, willing to use effective birth control methods during the study 5. provision of informed consent within 96 hours after hospitalization

inclusion criteria: 1. hospitalized or will be hospitalized prior to randomization for the treatment of severe covid-19 with sars-cov-2 infection confirmed by either a) a positive reverse transcriptase polymerase chain reaction (rt pcr) or b) an antigen-based test from any respiratory, nasopharyngeal, saliva, blood, or stool specimen at screening or documented within 1 week prior to the start of screening (severe covid-19 is defined as confirmed disease in patients who are hospitalized with hypoxia \[spo2 ≤93% on room air\], respiratory rate \>30, pao2/fio2 \<300, but do not require imv). 2. age ≥ 18 years 3. platelet count ≥ 50,000/µl 4. if fertile, willing to use effective birth control methods during the study 5. provision of informed consent within 96 hours after hospitalization

inclusion criteria: hospitalized or will be hospitalized prior to randomization for the treatment of severe covid-19 with sars-cov-2 infection confirmed by either a) a positive reverse transcriptase polymerase chain reaction (rt pcr) or b) an antigen-based test from any respiratory, nasopharyngeal, saliva, blood, or stool specimen at screening or documented within 1 week prior to the start of screening (severe covid-19 is defined as confirmed disease in patients who are hospitalized with hypoxia [spo2 ≤93% on room air], respiratory rate >30, pao2/fio2 <300, but do not require imv). age ≥ 18 years platelet count ≥ 50,000/µl if fertile, willing to use effective birth control methods during the study provision of informed consent within 96 hours after hospitalization

inclusion criteria: hospitalized or will be hospitalized prior to randomization for the treatment of severe covid-19 with sars-cov-2 infection confirmed by either a) a positive reverse transcriptase polymerase chain reaction (rt pcr) or b) an antigen-based test from any respiratory, nasopharyngeal, saliva, blood, or stool specimen at screening or documented within 1 week prior to the start of screening (severe covid-19 is defined as confirmed disease in patients who are hospitalized with hypoxia [spo2 ≤93% on room air], respiratory rate >30, pao2/fio2 <300, but do not require imv). age ≥ 18 years platelet count ≥ 50,000/µl if fertile, willing to use effective birth control methods during the study provision of informed consent within 96 hours after hospitalization

inclusion criteria: 1. hospitalized or will be hospitalized prior to randomization for the treatment of severe covid-19 with sars-cov-2 infection confirmed by either a) a positive reverse transcriptase polymerase chain reaction (rt pcr) or b) an antigen-based test from any respiratory, nasopharyngeal, saliva, blood, or stool specimen at screening or documented within 1 week prior to the start of screening (severe covid-19 is defined as confirmed disease in patients who are hospitalized with hypoxia [spo2 ≤93% on room air], respiratory rate >30, pao2/fio2 <300, but do not require imv). 2. age ≥ 18 years 3. platelet count ≥ 50,000/µl 4. if fertile, willing to use effective birth control methods during the study 5. provision of informed consent within 96 hours after hospitalization

inclusion criteria: 1. hospitalized or will be hospitalized prior to randomization for the treatment of severe covid-19 with sars-cov-2 infection confirmed by either a) a positive reverse transcriptase polymerase chain reaction (rt pcr) or b) an antigen-based test from any respiratory, nasopharyngeal, saliva, blood, or stool specimen at screening or documented within 1 week prior to the start of screening (severe covid-19 is defined as confirmed disease in patients who are hospitalized with hypoxia [spo2 ≤93% on room air], respiratory rate >30, pao2/fio2 <300, but do not require imv). 2. age ≥ 18 years 3. platelet count ≥ 50,000/µl 4. if fertile, willing to use effective birth control methods during the study 5. provision of informed consent within 96 hours after hospitalization